US Stock Insider Trading | Aureus Technology Disclosed 2 Company Insider Trading Transactions on March 16

K-LinePoet · 2026-03-25T22:36:36+00:00

Orasure Technologies (OSUR) disclosed insider trading information on March 16, 2026, in which director Eglinton Manner Carrie and executive McGrath Kenneth J each purchased 22,000 shares on March 13 at a transaction price of $3.00 per share, while McGrath previously sold 28,400 shares on March 1. The company focuses on the development and sales of oral fluid diagnostic products and medical devices.

K-LinePoet

2026-03-25 22:36:36

Abstract generation in progress

On March 16, 2026, Osur Technologies (OSUR) disclosed two insider transactions. Director EGLINTON MANNER CARRIE purchased 22,000 shares on March 13, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 16, 2026	Director	EGLINTON MANNER CARRIE	March 13, 2026	Buy	22,000	3.00	66,000
March 16, 2026	Executive	McGrath Kenneth J	March 13, 2026	Buy	22,000	3.00	66,000
March 3, 2026	Executive	McGrath Kenneth J	March 1, 2026	Sell	28,400	3.04	86,400
March 3, 2026	Director	EGLINTON MANNER CARRIE	March 1, 2026	Sell	178,800	3.04	543,900
December 19, 2025	Director	Kenny John P.	December 17, 2025	Buy	10,300	2.46	25,300
December 2, 2025	Director	Gagliano Nancy J	November 28, 2025	Buy	2,100	2.37	4,981.83
September 26, 2025	Director	Kenny John P.	September 24, 2025	Buy	6,118	3.27	20,000
June 25, 2025	Director	Kenny John P.	June 24, 2025	Buy	6,657	3.01	20,000
June 5, 2025	Director	EGLINTON MANNER CARRIE	June 4, 2025	Sell	193,200	2.90	560,400
May 15, 2025	Director	Aspinall Mara G., Gagliano Nancy J., Marmora Lelio, McMahon Robert W., Shulkin David	May 13, 2025	Sell	30,500	2.65	80,800

[Company Information]

Orasure Technologies, Inc. was founded in May 2000 under Delaware law. It merged with STC Technologies and Epitope, and changed Epitope’s location from Oregon to Delaware. The company’s main business involves developing, manufacturing, marketing, and selling oral liquid diagnostic products and sample collection devices using proprietary oral fluid technology, as well as other diagnostic products including immunoassays and other in vitro diagnostic reagents. The company also produces and sells medical devices for cryosurgical removal of benign skin lesions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.